by Pharvaris | Feb 1, 2021 | News
Zug, Switzerland, Feb. 1, 2021 – Pharvaris, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of...
by Pharvaris | Jan 27, 2021 | News
Data demonstrate the oral bioavailability of PHA121, which was well-tolerated across multiple ascending doses Zug, Switzerland, Jan. 27, 2021 – Pharvaris, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
by Pharvaris | Jan 5, 2021 | News
Zug, Switzerland, Jan. 5, 2021 – Pharvaris, a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today...
by Pharvaris | Nov 18, 2020 | News
New investors include Viking Global Investors, General Atlantic, and Cormorant Asset Management, with an expanded position by Venrock Healthcare Capital Partners Phase 2 study of PHVS416 expected to initiate in 2021 Zug, Switzerland, Nov. 18, 2020 – Pharvaris, a...
by Pharvaris | Nov 13, 2020 | News
PHA121 outperforms icatibant in a bradykinin-challenge study Zug, Switzerland, Nov. 13, 2020 – Pharvaris, a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema...
by Pharvaris | Jul 30, 2020 | News
Data further validate Pharvaris’ B2-receptor-antagonist program Zug, Switzerland, July 30, 2020 – Pharvaris, a clinical-stage company focused on the discovery and development of novel oral B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and...
